Home
BMRN
BMRN News

Latest BioMarin Pharmaceutical Inc. (BMRN) News on September 6, 2025

Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86

Insider Monkey

14 days ago

Barclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86

2 Reasons to Watch BMRN and 1 to Stay Cautious

StockStory

17 days ago

2 Reasons to Watch BMRN and 1 to Stay Cautious

BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A

Insider Monkey

2 months ago

BioMarin’s ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Zacks

2 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

The Top 5 Analyst Questions From BioMarin Pharmaceutical’s Q1 Earnings Call

StockStory

2 months ago

The Top 5 Analyst Questions From BioMarin Pharmaceutical’s Q1 Earnings Call

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Zacks

2 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Argus Research

2 months ago

BMRN: What does Argus have to say about BMRN?

MT Newswires

2 months ago

BioMarin Pharmaceutical Reports Sustained Efficacy for Hemophilia A Gene Therapy in Five-Year Data

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

PR Newswire

2 months ago

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating

Insider Monkey

2 months ago

Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating

2 Reasons to Watch BMRN and 1 to Stay Cautious

StockStory

2 months ago

2 Reasons to Watch BMRN and 1 to Stay Cautious

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

GlobeNewswire

3 months ago

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

Does The Market Have A Low Tolerance For BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Fundamentals?

Simply Wall St.

3 months ago

Does The Market Have A Low Tolerance For BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Fundamentals?

1 of Wall Street’s Favorite Stock to Target This Week and 2 to Think Twice About

StockStory

3 months ago

1 of Wall Street’s Favorite Stock to Target This Week and 2 to Think Twice About

Jim Cramer on BioMarin: “I Don’t Think It Works Now”

Insider Monkey

3 months ago

Jim Cramer on BioMarin: “I Don’t Think It Works Now”

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Argus Research

3 months ago

BMRN: Raising target price to $63.00

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Zacks

3 months ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Here Are All 6 Stocks I've Bought Through 5 Months of 2025

Motley Fool

3 months ago

Here Are All 6 Stocks I've Bought Through 5 Months of 2025

1 Mid-Cap Stock with Exciting Potential and 2 to Avoid

StockStory

3 months ago

1 Mid-Cap Stock with Exciting Potential and 2 to Avoid

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?

Zacks

3 months ago

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock?

2 Value Stocks with Exciting Potential and 1 to Steer Clear Of

StockStory

3 months ago

2 Value Stocks with Exciting Potential and 1 to Steer Clear Of

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

StockStory

3 months ago

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Zacks

3 months ago

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Zacks

3 months ago

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks

3 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Argus Research

4 months ago

BMRN: What does Argus have to say about BMRN?

Biotech Alert: Searches spiking for these stocks today

TipRanks

4 months ago

Biotech Alert: Searches spiking for these stocks today

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

Zacks

4 months ago

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

BioMarin agrees to acquire Inozyme for $270m

Pharmaceutical Technology

4 months ago

BioMarin agrees to acquire Inozyme for $270m

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition

Insider Monkey

4 months ago

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

TipRanks

4 months ago

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

MT Newswires

4 months ago

Top Midday Gainers

BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover

Investor's Business Daily

4 months ago

BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover

MT Newswires

4 months ago

Sector Update: Health Care Stocks Flat to Higher Premarket Friday

MT Newswires

4 months ago

Sector Update: Health Care

MT Newswires

4 months ago

BioMarin Pharmaceutical to Acquire Inozyme Pharma for $270 Million

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

PR Newswire

4 months ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress

StockStory

4 months ago

BMRN Q1 Earnings Call: BioMarin Outperforms on Revenue and Expands Pipeline Progress

BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Insider Monkey

4 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying

Argus Research

4 months ago

BMRN: Rating increased to a BUY

MT Newswires

4 months ago

BioMarin's Voxzogo Reduces Tibial Bowing in Young Children With Achondroplasia

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

PR Newswire

4 months ago

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

Shareholders Will Be Pleased With The Quality of BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings

Simply Wall St.

4 months ago

Shareholders Will Be Pleased With The Quality of BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Zacks

4 months ago

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential

Insider Monkey

4 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential

1 Healthcare Stock with Competitive Advantages and 2 to Brush Off

StockStory

4 months ago

1 Healthcare Stock with Competitive Advantages and 2 to Brush Off

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

StockStory

4 months ago

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

StockStory

4 months ago

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years

Insider Monkey

4 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years

Argus Research

4 months ago

BMRN: Lowering target price to $63.00

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Zacks

4 months ago

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

Zacks

4 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

StockStory

4 months ago

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow

StockStory

4 months ago

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow

Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow

StockStory

4 months ago

Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow

BioMarin Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations

Simply Wall St.

4 months ago

BioMarin Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations

Morningstar Research

4 months ago

Analyst Report: BioMarin Pharmaceutical Inc.

BioMarin's First-Quarter Earnings & Sales Beat Estimates

Zacks

4 months ago

BioMarin's First-Quarter Earnings & Sales Beat Estimates

Thomson Reuters StreetEvents

4 months ago

Q1 2025 BioMarin Pharmaceutical Inc Earnings Call

Biomarin Pharmaceutical Inc (BMRN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

4 months ago

Biomarin Pharmaceutical Inc (BMRN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

4 months ago

BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates

Zacks

4 months ago

BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates

BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets

StockStory

4 months ago

BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets

MT Newswires

4 months ago

BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Rise

Associated Press Finance

4 months ago

BioMarin: Q1 Earnings Snapshot

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

PR Newswire

4 months ago

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

StockStory

4 months ago

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

Insider Monkey

4 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

2 Cash-Producing Stocks with Exciting Potential and 1 to Question

StockStory

4 months ago

2 Cash-Producing Stocks with Exciting Potential and 1 to Question

BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying

Insider Monkey

4 months ago

BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Zacks

4 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Implied Volatility Surging for BioMarin Stock Options

Zacks

4 months ago

Implied Volatility Surging for BioMarin Stock Options

Argus Research

4 months ago

BMRN: Raising target price to $65.00

1 of Wall Street’s Favorite Stock Worth Your Attention and 2 to Question

StockStory

4 months ago

1 of Wall Street’s Favorite Stock Worth Your Attention and 2 to Question

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Zacks

5 months ago

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

5 months ago

Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

PR Newswire

5 months ago

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Zacks

5 months ago

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Zacks

5 months ago

Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

StockStory

5 months ago

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

Argus Research

5 months ago

BMRN: Raising target price to $63.00

MT Newswires

5 months ago

Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin

6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility

Motley Fool

5 months ago

6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?

Zacks

5 months ago

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Zacks

5 months ago

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day

Zacks

5 months ago

Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day

Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On

Zacks

5 months ago

Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On

Argus Research

5 months ago

BMRN: Lowering target price to $59.00

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

Zacks

5 months ago

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

Zacks

5 months ago

3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)

What Makes BioMarin (BMRN) a New Buy Stock

Zacks

5 months ago

What Makes BioMarin (BMRN) a New Buy Stock

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks

5 months ago

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Zacks

5 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

StockStory

5 months ago

Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Zacks

5 months ago

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

StockStory

5 months ago

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint

Clinical Trials Arena

5 months ago

BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint

BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients

Benzinga

5 months ago

BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients

MT Newswires

5 months ago

BioMarin's Trial for Phenylketonuria Shows Palynziq Reduces Blood Phenylalanine in Adolescents

Share on Social Networks: